News | Coronavirus (COVID-19) | February 24, 2021

Cardiovascular Admissions Reduced in U.K. During a Second Wave of COVID-19

Evidence continues to mount showing more than a third of U.K. patients are ignoring heart attack and acute heart failure symptoms

UK hospU.K. hospital admissions for heart attacks and heart failure were reduced by more than 50 percent in the spring of 2020 and by more than a third in the second wave of COVID-19 as people fear going to hospitals and ignore serious symptoms.ital admissions for heart attacks and heart failure have been reduced by COVID-19 as people fear going to hospitals. Getty Images #COVIDUK #COVID19

U.K. hospital admissions for heart attacks and heart failure were reduced by more than 50 percent in the spring of 2020 and by more than a third in the second wave of COVID-19 as people fear going to hospitals and ignore serious symptoms. Getty Images


February 24, 2021 — A study of admissions for acute myocardial infarction (AMI) and heart failure (HF) in the U.K. decreased by 41% and 34% respectively during the second wave of the COVID-19 panademic in the fall of 2020. The first wave in March 2020 saw a 54% decrease in admissions.[1]

The first wave of the COVID-19 pandemic was associated with a decline in admissions for cardiovascular disease. Many cardiologists remain concerned that the decline was related to care-seeking behavior rather than a change in incidence. These investigators used national U.K. databases to determine whether the second lockdown in the U.K. was accompanied by a similar decline in admissions.

In a sample of “rapid reporting” hospitals, the researchers identified 62,683 admissions for heart failure and acute myocardial infarction (AMI) between November 1, 2018, and November 17, 2020. During the first lockdown, which began in March 2020, daily hospitalizations for heart failure and AMI declined by 54%. The rates began to increase during April and almost returned to baseline by June. Beginning with the second lockdown in October 2020, admissions again declined, with decreases of 41% in hospitalizations for heart failure and 34% for AMI. For context, the admission rates for 2018 varied little from the 2019 rates.

The authors wrote that despite an initial recovery in admissions with HF and MI, the latter part of 2020 has witnessed a second decline in people hospitalized with these conditions, which pre-dated the onset of the second national lockdown in the United Kingdom. The second dip appears of similar magnitude to that of the first and signals that the public are fearful of attending hospitals despite having medical emergencies, and that this varies over time, possibly relating to numbers of cases and social mandates. This is important because earlier work from the United Kingdom described how delays to seeking help were temporally related to an inflation in deaths from a range of acute cardiovascular diseases. The authors said the decline in admissions requires clear public messaging to prevent further unintended consequences with increased deaths and poor outcomes due to delays in cardiac care.

 

Related Cardiology COVID Content:

VIDEO: Where Have all the STEMI Cases Gone Amid COVID-19? — Interview with Thomas Maddox, M.D.

Rapid Drop in Heart Attacks and Stroke at Hospitals Concerns ACC 

VIDEO: Patients Fear COVID More than Heart Attacks — Interview with Cindy Grines, M.D.

SCAI Study Shows COVID Fears Continue to Cause Americans to Avoid Doctor Visits

The Long-term Cardiovascular Impact of COVID-19

Cardiologists Should Prioritize Influenza Vaccination Amidst COVID-19 Pandemic

Find more cardiology related COVID-19 content

 

Reference:

1. Jianhua Wu, Mamas A. Mamas, Mar A. de Belder, John E.Deanfield, Chris P.Gale. Second decline in admissions with heart failure and myocardial infarction during the COVID-19 pandemic. J Am Coll Cardiol. Published online 2021 Jan 12. https://doi.org/10.1016/j.jacc.2020.12.039.


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now